Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 794 | 75 | 663 |
| Samples | 214 | 36 | 171 |
| Peptides | 192 | 26 | 158 |
Function
ZNF384 · Zinc finger protein 384
This gene encodes a C2H2-type zinc finger protein, which may function as a transcription factor. This gene also contains long CAG trinucleotide repeats that encode consecutive glutamine residues. The protein appears to bind and regulate the promoters of the extracellular matrix genes MMP1, MMP3, MMP7 and COL1A1. Studies in mouse suggest that nuclear matrix transcription factors (NP/NMP4) may be part of a general mechanical pathway that couples cell construction and function during extracellular matrix remodeling. Alternative splicing results in multiple transcript variants. Recurrent rearrangements of this gene with the Ewing's sarcoma gene, EWSR1 on chromosome 22, or with the TAF15 gene on chromosome 17, or with the TCF3 (E2A) gene on chromosome 19, have been observed in acute leukemia. A related pseudogene has been identified on chromosome 7. [provided by RefSeq, Apr 2011].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000361959 | Q8TF68 | 211 | 172 |
| ENST00000396801 | Q8TF68 | 209 | 170 |
| ENST00000319770 | Q8TF68-2 | 184 | 150 |
| ENST00000355772 | Q8TF68-3 | 162 | 133 |
| ENST00000683879 | A0A804HJE2* | 28 | 25 |
Gene Properties
Recurrent Mutations
All 172 amino-acid changes on canonical ENST00000361959 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ZNF384 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ZNF384 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 6/612 1% |
| Melanoma | 3/210 1% | 23/1899 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Colorectal Carcinoma | 10/143 7% | 27/3239 1% |
| Other Solid Cancers | 0/94 0% | 15/1515 1% |
| Gastric Carcinoma | 1/74 1% | 16/1809 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Head and Neck Carcinoma | 0/85 0% | 10/1574 1% |
| Bladder Carcinoma | 1/58 2% | 5/956 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 6/1390 0% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Neuroendocrine Tumour | 0/154 0% | 3/577 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Non-Cancerous | 2/104 2% | 1/830 0% |
| Hepatocellular Carcinoma | 0/46 0% | 7/2210 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 7/2550 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Breast Carcinoma | 0/144 0% | 8/3264 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 2/1592 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 4/2534 0% |
| Other Blood Cancers | 0/61 0% | 4/2725 0% |
| Neuroblastoma | 0/87 0% | 2/1331 0% |
Mutation Distribution
Where ZNF384 is mutated · all tissues, split by cell line vs tissue
How many mutations in ZNF384 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 794 mutations in ZNF384
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|